Target · BACE1
BACE1
BACE1 inhibition produces robust amyloid-pathology readouts but has failed in trials, with toxicity attributed to non-APP substrates.
All 19 claims
Sorted by confidence. Click any to read the evidence.
Verubecestat (BACE1 inhibitor) Phase III EPOCH trial in mild-moderate AD halted for futility; cognitive worsening signal observed. Production-side amyloid intervention failed alongside MAb clearance approaches, narrowing therapeutic-window viability of the amyloid hypothesis.
Covers Genentech's low-affinity anti-TfR antibodies that facilitate BBB transcytosis without inhibiting transferrin or HFE binding; foundational patent on affinity-tuning TfR antibodies to escape lysosomal trapping and achieve CNS delivery.
Re-engineering of the anti-transferrin receptor antibody 8D3 to monovalent binding increases BBB transcytosis efficiency 10-fold over bivalent format; monovalent TfR engagement avoids receptor downregulation and enables superior brain uptake of antibody-drug conjugates.
Lanabecestat phase 3 trials were stopped for futility, adding class-level pressure against broad BACE1 inhibition as an Alzheimer's disease treatment strategy.
Reducing anti-TfR antibody affinity for transferrin receptor enhances receptor-mediated transcytosis and brain uptake; bispecific anti-TfR/BACE1 antibody lowers brain Aβ in mice after single systemic dose. Mechanistic foundation of the Brain Shuttle delivery class.
Anti-TfR/BACE1 bispecific antibodies cross BBB in cynomolgus monkeys; reduce CSF and brain-tissue Aβ in dose-dependent fashion correlated with brain antibody concentration. Translates Yu 2011 mouse PK/PD into NHP, supporting clinical Brain Shuttle development.
Verubecestat failed in prodromal Alzheimer's disease and raised concern that BACE1 inhibition can worsen cognition.
Verubecestat failed to improve cognition or function in mild-to-moderate Alzheimer's disease despite BACE1 target engagement.
Merck patent on iminothiadiazine dioxide scaffold BACE inhibitors encompassing the verubecestat (MK-8931) compound class; covers C2-ring-substituted variants of the thiadiazinane core used in the EPOCH and APECS Phase 3 trials.
Atabecestat development was halted after liver toxicity signals, separating BACE1 target engagement from acceptable translational safety.
Lanabecestat (LY3314814) AMARANTH/DAYBREAK Phase III trials terminated for futility in 2018; class effect of BACE1 inhibition on cognition strengthened by APECS prior.
BACE1 inhibitor trials of verubecestat and atabecestat failed.
Transferrin-receptor shuttle designs can increase brain exposure of anti-BACE or anti-amyloid antibodies in preclinical systems, but clinical translation remains unresolved.
Which non-APP BACE1 substrates explain cognitive worsening or toxicity in failed BACE inhibitor trials?
Verubecestat APECS trial in prodromal AD also failed; cognitive worsening replicated in the earlier-stage population. Class concern about BACE1 inhibitor cognitive harm — likely off-target via non-APP BACE1 substrates (e.g. neuregulin-1, seizure protein 6).
Anti-TfR/BACE1 bispecific antibodies cross the blood-brain barrier and reduce brain amyloid-beta levels in human TfR knock-in mice.
Failed BACE1 inhibitor trials produce a measurable, directional confidence drift in the evidence graph for the amyloid cascade hypothesis. Predictions: Confidence weights on amyloid-cascade-supporting edges will decrease following the publication dates of the failed trials.; Targets downstream of BACE1 will show...
How should failed BACE1 inhibitor trials (verubecestat, atabecestat) be represented as confidence drift in the evidence graph?
The reduction of brain amyloid-beta by anti-TfR/BACE1 antibodies in human TfR knock-in mice is dependent on the antibody's affinity for the transferrin receptor.